Boryung’s Gastrointestinal gelfos-M enter the US market

Pharmaceutical company Boryung gelfos-M will enter the US market.

Boryung four days has stated that it will be sold in the United States since the end of April to begin March 31 gelfos-M initial volume shipment.

Currently, the US market is last in 2014 Gastrointestinal IMS standards mutator about 20 billion dollars’ frill to section OTC` as (worth about 2.2 trillion won) (Prilosec OTC), ‘Nexium 24-hour’ (Nexium 24-hour) We lead the market.

Boryung was explained that plans to lead this world and OTC drugs (OTC) market as the world’s No. 1 goal antacids foothold in the US market in the Chinese market.
In addition, “We are planning to release new products for this year expanded the brand lineup” and “sustainable revenue growth is expected,” he adds.
gelfos-M is the first time in 1975 after being released as a domestic gelfos improve the efficacy and notch ingredients birth in 2000 to the newly re products.

Distributed by PRWorldwire

Media Contact
Company Name: PRWorldwire
Contact Person: Media Relations
Phone: +82-10-7180-7934
Country: Korea